RL vs ZBIO · P/E 24, rev $8.11B vs rev $5.0M
Ralph Lauren Corp Class A (RL) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
Ralph Lauren Corp Class A (RL) is a apparel manufacturing company listed on US.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported RL revenue for 2026-03-28 was $8.11B. Net income was $941.1M. Revenue was up 14.6% from 2025-03-29 to 2026-03-28. RL currently screens at market cap $16.95B and trailing P/E 24.1.
Latest reported ZBIO revenue for 2024-12-31 was $5.0M. Net income was -$157.0M. Revenue was down 90.0% from 2023-12-31 to 2024-12-31. ZBIO currently screens at market cap $798.0M.
RL currently screens at market cap $16.95B and trailing P/E 24.1. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the RL and ZBIO stock pages for the full models.
Not investment advice.